Metabolic and anti-fibrogenic outcomes of targeting the protease Fibroblast Activation Protein (FAP) — ASN Events

Metabolic and anti-fibrogenic outcomes of targeting the protease Fibroblast Activation Protein (FAP) — ASN Events

Metabolic and anti-fibrogenic outcomes of targeting the protease Fibroblast Activation Protein (FAP)

Metabolic and anti-fibrogenic outcomes of targeting the protease Fibroblast Activation Protein (FAP) (#85)

Mark Gorrell ¹ , Sumaiya Chowdhury ¹ , Xin M Wang ¹ , William W Bachovchin ² , Geoffrey W McCaughan ¹ , Susan V McLennan ³ , Stephen M Twigg ³

Centenary Institute, Sydney, NSW, Australia
Biochemistry, Tufts University, Boston, MA, USA
Endocrinology, University of Sydney, Sydney, NSW, Australia

Publish consent withheld

Authors contributing to this presentation.

Gorrell, M

Associate Professor Mark Gorrell has a PhD from Australian National University and conducted postdoctoral studies at University of Melbourne and Johns Hopkins University School of Medicine. He heads a liver disease pathogenesis, dipeptidyl peptidases and diabetes research group at the Centenary Institute in Sydney. He has authored 109 papers and patents, primarily on DPP4 and related proteases and on liver disease pathogenesis, is treasurer of the International Proteolysis Society and is on 3 editorial boards.

Chowdhury, S

Wang, X.M

Bachovchin, W.W

McCaughan, G.W

McLennan, S.V

Twigg, S.M